Executive Chairman – Dan Stinchcomb
Dr. Stinchcomb is Founder and Principal of Global H, LLC a scientific consulting group that advises vaccine and infectious disease groups worldwide. Dr. Stinchcomb is Senior Scientific Advisor to Takeda Vaccines Business Division, Chief Scientific Advisor to PharmaJet, Inc., a reviewer for the Global Health Innovation Technology Fund and is on the board of several vaccine companies. Previously, Dr. Stinchcomb was President and Chief Executive Officer of Inviragen, which he co-founded in 2005. Under his leadership, Inviragen grew from a two-employee start-up to an international clinical stage company focusing on infectious disease vaccines. Inviragen was successfully acquired by Takeda in May of 2013. Dr. Stinchcomb has twenty-five years of biotechnology experience including research, product development, and approval of vaccines, therapeutics, and diagnostics. His background includes positions as Executive Vice President of Research and Development at Heska Corporation, senior scientific management positions at Ribozyme Pharmaceuticals (acquired by Merck) and at Synergen (acquired by Amgen) as well as Associate Professor in Cellular and Developmental Biology at Harvard University. Dr. Stinchcomb holds a B.A. in biology from Harvard College and a Ph.D. in biochemistry from Stanford University.
Mr. Clarke’s original training in the pharmaceutical and vaccine industry was received at Merck and Company, where he held several positions, including Vice President of the Merck Vaccine Division and the founding President of Pasteur-Merieux MSD, a European joint venture that commercialized vaccines in the European Union. Since leaving Merck in 1996, his career has focused on leading and advising smaller developmental biotechnology and vaccine companies. Mr. Clarke was previously President and Chief Executive Officer of three biotechnology companies: Neose Technologies, a protein therapeutics company; Aviron, a vaccine company; and U.S. Bioscience, an oncology company. MedImmune acquired both Aviron (in 2001) and U.S. Bioscience (in 1999) for a combined value of $2 billion. Mr. Clarke has served as Chairman of the Board of QLT (an ocular company) and Mersana Therapeutics (an oncology company), and as Executive Chairman of LigoCyte Pharmaceuticals (a vaccine company), in which he oversaw the sale of the company to Takeda Pharamceuticals in 2012. He has also served as a board member or advisor to OraVax (a vaccine company) and Rib-X (an antibiotic company). In these capacities, he has developed significant expertise in the challenges of small company leadership, strategic management, business development, and mergers and acquisitions.
Michael Falk is the General Counsel for the Wisconsin Alumni Research Foundation, the patent management and licensing organization of the University of Wisconsin–Madison. Mr. Falk is responsible for a staff of a dozen legal and intellectual property professionals who oversee WARF’s patent program and manage its legal affairs. Before joining WARF, Mr. Falk practiced as a patent litigator with Foley & Lardner’s Madison office.
Mr. Falk completed his undergraduate degree at Columbia University and earned a J.D., M.B.A. and an M.S. in bacteriology from the University of Wisconsin–Madison. He graduated cum laude from the law school where he served as articles editor for the Wisconsin Law Review and is a member of Order of the Coif. Mr. Falk serves on numerous University of Wisconsin-Madison affiliated boards, including the Wisconsin Center for Education Products and Services, the Waisman Board of Visitors, and the Office of Industrial Partnerships Advisory Board. He has also been active in serving on boards of WARF portfolio companies, including most notably Cellular Dynamics International as that company went public.
Mr. Falk additionally serves as adjunct professor in the University of Wisconsin-Madison School of Medicine and Public Health and as lead instructor in the intellectual property component of the Master of Science in Biotechnology Program.
Phillip M. Halpern
Philip M. Halpern is the managing partner of the law firm of Collier, Halpern, Newberg, Nolletti & Bock, LLP, with offices in New York City, White Plains and Stamford, Connecticut. Mr. Halpern is a magna cum laude graduate of Fordham University, where he majored in economics, and is a graduate of Pace University School of Law where he obtained his juris doctor.
Mr. Halpern actively practices law in the states of New York and Connecticut. He has been certified by the National Board of Trial Advocacy as a civil trial advocate and civil pre-trial advocate. Mr. Halpern has recently authored a two-volume book for Thompson Publishing Company on civil procedure (with annual updates). He is presently working on a new text book entitled “The Anatomy of a Trial.” He has also authored several articles for the New York State Bar Association and the American Bar Association and has lectured for the Office of Court Administration, New York State Bar Association, Pace University School of Law and a number of Bar Associations on a variety of litigation topics. His articles include “Age Discrimination in Employment: Releases Protect Employers Too!” which was published in The Labor Lawyer, American Bar Association, in 1993, “Fair Value Proceedings: Fixing Fair Value In New York,” which was published in the NY Litigator, New York State Bar Association, Commercial and Federal Litigation Section, in 1996, “Court of Appeals Sharply Diminishes the Substantive Due Process Rights of Property Owners,” which was published in The NY Litigator, New York State Bar Association, Commercial and Federal Litigation Section, in 2006, “Unlocking a Valuable Tool: Summary Judgment Hearings on Issues of Fact,” published in the Westchester Bar Journal, Westchester County Bar Association in 2006 and “The Contours of Common-Law Dissolution in New York,” published in the NY Litigator, New York State Bar Association, Commercial and Federal Litigation Section in 2007. Mr. Halpern is currently teaching at Pace Law School as an adjunct Professor.
Mr. Halpern is a Fellow of the American Bar Foundation and member of the Office of Court Administration’s Advisory Committee on Civil Practice. Mr. Halpern has been a member of the Advisory Council for the Board of Judges for the Southern District of New York. Mr. Halpern is a member of the Association of the Bar of the City of New York, the Committee on Federal Judiciary for the New York State Bar Association, the American Bar Association, the New York County Lawyers Association, New York State Trial Lawyers Association, the Association of Trial Lawyers of America, and the Federal Bar Council. Mr. Halpern began his legal career in 1980 as a law clerk to a federal judge in the Southern District of New York.
Mr. Halpern joined the Westchester Country Club in June 1984, was its President from 2007 to 2010 and formerly held the office of Chairman from 2010-2013. Additionally, Mr. Halpern is a member of the Advisory Council for the Metropolitan Section of the Professional Golfer’s Association, the Hudson Valley KeyBank Advisory Board, the Board of Directors of the Montel Williams MS Foundation, and the Board of Visitors of Pace University School of Law. He is the 2006 recipient of the Alumni Leadership Award from Pace Law School, the 2007 Pace Setter Award from the Westchester Business Journal and in 2008 was honored by the American Diabetes Association as Father of the Year.
Paul V. Radspinner
Mr. Radspinner is co-founder, President and Chief Executive Officer of FluGen Inc. After completing his MBA at Northwestern University’s Kellogg Graduate School of Management he spent over 15 years in management roles overseeing international pharmaceutical operations, marketing and business development with Eli Lilly and Company. Subsequent to his time at Lilly he managed the pharmaceuticals portfolio including Vitamin D analogs at the Wisconsin Alumni Research Foundation (WARF) for the University of Wisconsin-Madison. Most recently, Mr. Radspinner took on the role of Vice President of Business Development for Deltanoid Pharmaceuticals, Inc. before he started FluGen with Drs. Yoshihiro Kawaoka and Gabriele Neumann in June of 2007. FluGen has raised nearly $20 million in capital thus far and initiated its first-in-man study of M2SR “RedeeFlu” this past summer. In 2008 Mr. Radspinner was elected to the Board of Directors for BioForward, the Wisconsin state biotechnology organization where he served as President. Mr. Radspinner is a member of the Boards of Directors for Pan Genome Sciences and Co-D Therapeutics Inc.
Mr. Walsh is a retired Partner and former managing partner in the law firm Foley & Lardner LLP. He received his bachelor’s degree, with honors, from the University of Wisconsin-Madison. In 1997 he received the Distinguished Business Alumnus Award from the University’s School of Business and in 2012 he received the Distinguished Alumnus Award from the University of Wisconsin-Madison. His J.D. degree was conferred by Harvard Law School. Mr. Walsh was Chair of the UW Hospital and Clinics Authority Board from 2008 – 2015. He served on the University of Wisconsin System Board of Regents from 2003-2015, where he served as President from 2005-2007. Mr. Walsh is also a Board member of Thompson Investment Management, LLC, National Guardian Life Insurance Company, the University of Wisconsin Research Park, Inc., and is on the investment committee for the Kegonsa Seed Fund I, L.P.
Paul joined Venture Investors in 2006, as a Managing Director. He focuses on making Healthcare investments and is an active member in the firm’s Venture Igniter program.
Paul has over 25 years of operating experience in the biotech and pharmaceutical industries. He previously was President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma Solutions). Before joining Gala, Paul served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a biotechnology company that completed its IPO during his tenure and was subsequently acquired by Johnson & Johnson. Earlier in his career, Paul worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals, a division of American Home Products (Wyeth is now part of Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs (SPL), a division of American Home Products, prior to its spin-out. Paul began his career in industry as the Director of Operations for Columbia Research Labs, a small, publicly-held company that focuses on women’s health.
Paul is currently a member of the Board of Directors for Aerpio Therapeutics, FluGen, Madison Vaccines, and Neurovance. He is also an observer for Tissue Regeneration Systems. In addition, Paul serves on the Board of Directors for Tamir Biotechnology, Inc. (formerly Alfacell Corporation), the Waisman Center Board of Visitors, and the Waisman Center Biomanufacturing Facility Advisory Board. Paul was previously on the board of Akebia Therapeutics, prior to it going public in 2014 (NASDAQ: AKBA).
Paul received a B.S. in Biochemistry with honors from Carleton University-Ottawa, Ontario, a Ph.D. in Biochemistry and an MBA from the University of Wisconsin-Madison, where he also worked as a postdoctoral research associate.